Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCP2 | P22307 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 10/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 2/20 | 0.36 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.36 |
| ▸ | ATP4A | P20648 | 1/20 | 0.36 |
| ▸ | ATP4B | P51164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18070239 | 0.83 | MEN1 (0.62) | SCP2MEN1NPC1POLBRAB9A | |
| SCHEMBL16696324 | 0.82 | MEN1 (0.61) | SCP2MEN1NPC1POLBRAB9A | |
| Nile Blue SCHEMBL29356294 | 0.82 | MEN1 (0.77) | SCP2MEN1NPC1POLBRAB9A | |
| Nile Blue SCHEMBL12393690 | 0.82 | MEN1 (0.77) | SCP2MEN1NPC1POLBRAB9A | |
| SCHEMBL62370 | 0.80 | SCP2 (0.77) | SCP2MEN1NPC1POLBRAB9A | |
| SCHEMBL14267415 | 0.79 | SCP2 (0.56) | SCP2MEN1NPC1POLBRAB9A | |
| SCHEMBL19646592 | 0.79 | SCP2 (0.77) | SCP2MEN1NPC1POLBRAB9A | |
| SCHEMBL14267417 | 0.79 | SCP2 (1.00) | SCP2MEN1NPC1POLBRAB9A | |
| SCHEMBL23733292 | 0.78 | MEN1 (0.58) | SCP2MEN1NPC1POLBRAB9A | |
| SCHEMBL12393695 | 0.78 | MEN1 (0.59) | SCP2MEN1NPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263249-A1 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263249-A1 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOF | CD68, MSR1, CD47 | SCP2 2344/4885MEN1 498/4885NPC1 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.